Keyphrases
Acute Coronary Syndrome
100%
Dual Antiplatelet Therapy
100%
Ultra-low Dose
100%
Prothrombotic Status
100%
Rivaroxaban
100%
Thrombosis
100%
Antithrombotic Therapy
75%
Lysis
75%
Bleeding Risk
50%
Thrombus
50%
Thrombus Formation
50%
ST-elevation Myocardial Infarction (STEMI)
50%
Global Thrombosis Test
25%
Patient Identification
25%
Arterial Flow
25%
Bleeding
25%
Infarction
25%
Antiplatelet Agents
25%
Venous Thrombus
25%
Tissue Plasminogen Activator (t-PA)
25%
Antiplatelet Drugs
25%
Flow Condition
25%
Low Risk
25%
Thrombolysis
25%
Arterial Occlusion
25%
Low Shear Rate
25%
Thrombotic Events
25%
Thrombotic Complications
25%
Coronary Artery Occlusion
25%
Adverse Cardiac Events
25%
Antithrombotic Agents
25%
Low-risk Group
25%
Fibrinogen
25%
High Shear
25%
Stent Thrombosis
25%
Plaque Erosion
25%
Plaque Rupture
25%
Anticoagulant Medications
25%
Occlusion
25%
Stable Angina
25%
Rotational Thromboelastometry (ROTEM)
25%
Plasminogen Activator inhibitor-1 (PAI-1)
25%
Medicine and Dentistry
Antiplatelet
100%
Rivaroxaban
100%
Low Drug Dose
100%
Thrombosis
100%
Acute Coronary Syndrome
100%
Thrombus
50%
Antithrombotic
50%
Blood Clotting
33%
Coronary Occlusion
16%
Bleeding
16%
Fibrinogen
16%
Infarction
16%
Unstable Angina Pectoris
16%
Artery Blood Flow
16%
Antiplatelet Drug
16%
Antithrombotic Agent
16%
Antithrombotic Therapy
16%
Thrombolytic Drug
16%
Plasminogen Activator Inhibitor-1
16%
Low Risk Population
16%
ST Segment Elevation Myocardial Infarction
16%
Non ST Segment Elevation Myocardial Infarction
16%
Artery Occlusion
16%
Major Adverse Cardiac Event
16%
Carboxypeptidase B2
16%
Blood Clot Lysis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Rivaroxaban
100%
Acute Coronary Syndrome
100%
Thrombosis
100%
Antiplatelet
100%
Thrombus
83%
Anticoagulant Agent
66%
Coronary Artery Occlusion
16%
Fibrinolytic Agent
16%
Fibrinogen
16%
Unstable Angina Pectoris
16%
Thrombin Activatable Fibrinolysis Inhibitor
16%
Bleeding
16%
Artery Occlusion
16%
Antithrombotic Therapy
16%
Infarction
16%
Major Adverse Cardiac Event
16%
Antithrombocytic Agent
16%
Non ST Segment Elevation Myocardial Infarction
16%
ST Segment Elevation Myocardial Infarction
16%